Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 431

1.

MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21.

Vilgelm AE, Saleh N, Shattuck-Brandt R, Riemenschneider K, Slesur L, Chen SC, Johnson CA, Yang J, Blevins A, Yan C, Johnson DB, Al-Rohil RN, Halilovic E, Kauffmann RM, Kelley M, Ayers GD, Richmond A.

Sci Transl Med. 2019 Aug 14;11(505). pii: eaav7171. doi: 10.1126/scitranslmed.aav7171.

PMID:
31413145
2.

Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology

Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A, Stewart GC, Choueiri TK, Di Carli M, Allenbach Y, Kumbhani DJ, Heinzerling L, Amiri-Kordestani L, Lyon AR, Thavendiranathan P, Padera R, Lichtman A, Liu PP, Johnson DB, Moslehi J.

Circulation. 2019 Jul 2;140(2):80-91.

PMID:
31390169
3.

A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis.

Johnson DB, McDonnell WJ, Gonzalez-Ericsson PI, Al-Rohil RN, Mobley BC, Salem JE, Wang DY, Sanchez V, Wang Y, Chastain CA, Barker K, Liang Y, Warren S, Beechem JM, Menzies AM, Tio M, Long GV, Cohen JV, Guidon AC, O'Hare M, Chandra S, Chowdhary A, Lebrun-Vignes B, Goldinger SM, Rushing EJ, Buchbinder EI, Mallal SA, Shi C, Xu Y, Moslehi JJ, Sanders ME, Sosman JA, Balko JM.

Nat Med. 2019 Aug;25(8):1243-1250. doi: 10.1038/s41591-019-0523-2. Epub 2019 Jul 22.

PMID:
31332390
4.

Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis.

Lu S, Stein JE, Rimm DL, Wang DW, Bell JM, Johnson DB, Sosman JA, Schalper KA, Anders RA, Wang H, Hoyt C, Pardoll DM, Danilova L, Taube JM.

JAMA Oncol. 2019 Jul 18. doi: 10.1001/jamaoncol.2019.1549. [Epub ahead of print]

PMID:
31318407
5.

Acidithiobacillus sulfuriphilus sp. nov.: an extremely acidophilic sulfur-oxidizing chemolithotroph isolated from a neutral pH environment.

Falagán C, Moya-Beltrán A, Castro M, Quatrini R, Johnson DB.

Int J Syst Evol Microbiol. 2019 Jul 5. doi: 10.1099/ijsem.0.003576. [Epub ahead of print]

PMID:
31274405
6.

Correlates of response and outcomes with talimogene laherperpvec.

Zhou AY, Wang DY, McKee S, Ye F, Wen CC, Wallace DE, Ancell KK, Conry RM, Johnson DB.

J Surg Oncol. 2019 Sep;120(3):558-564. doi: 10.1002/jso.25601. Epub 2019 Jul 2.

PMID:
31264725
7.

Empiric Therapy with BRAF and MEK Inhibitors in Metastatic Melanoma.

Cann CG, Tillman BF, Davis EJ, Johnson DB.

Oncologist. 2019 Jun 18. pii: theoncologist.2019-0332. doi: 10.1634/theoncologist.2019-0332. [Epub ahead of print]

PMID:
31213499
8.

Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis.

Salem JE, Allenbach Y, Vozy A, Brechot N, Johnson DB, Moslehi JJ, Kerneis M.

N Engl J Med. 2019 Jun 13;380(24):2377-2379. doi: 10.1056/NEJMc1901677. No abstract available.

PMID:
31189043
9.

Displaced Meniscus Tear in the Acute Postoperative Period After Total Hip Arthroplasty: A Case Report.

Johnson DB Jr, Triplet JJ, Streit AR, Long NK, Wasielewski RC.

JBJS Case Connect. 2019 Apr-Jun;9(2):e0124. doi: 10.2106/JBJS.CC.18.00124.

PMID:
31188794
10.

Identification of Targetable Recurrent MAP3K8 Rearrangements in Melanomas Lacking Known Driver Mutations.

Lehmann BD, Shaver TM, Johnson DB, Li Z, Gonzalez-Ericsson PI, Sánchez V, Shyr Y, Sanders ME, Pietenpol JA.

Mol Cancer Res. 2019 Jun 11. doi: 10.1158/1541-7786.MCR-19-0257. [Epub ahead of print]

PMID:
31186280
11.

Upconversion of Cellulosic Waste Into a Potential "Drop in Fuel" via Novel Catalyst Generated Using Desulfovibrio desulfuricans and a Consortium of Acidophilic Sulfidogens.

Mikheenko IP, Gomez-Bolivar J, Merroun ML, Macaskie LE, Sharma S, Walker M, Hand RA, Grail BM, Johnson DB, Orozco RL.

Front Microbiol. 2019 May 10;10:970. doi: 10.3389/fmicb.2019.00970. eCollection 2019.

12.

Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study.

Johnson DB, Manouchehri A, Haugh AM, Quach HT, Balko JM, Lebrun-Vignes B, Mammen A, Moslehi JJ, Salem JE.

J Immunother Cancer. 2019 May 22;7(1):134. doi: 10.1186/s40425-019-0617-x.

13.

Immunotherapy in Older Adults with Cancer.

Godby RC, Johnson DB, Williams GR.

Curr Oncol Rep. 2019 May 7;21(7):56. doi: 10.1007/s11912-019-0806-2. Review.

PMID:
31065907
14.

Tumor genomic alterations in severe-combined immunodeficiency bare-lymphocyte syndrome genes are associated with high mutational burden and disproportional neo-antigen rates.

Wang Y, Johnson DB, Lu S, Diaz LA Jr, Xu Y, Balko JM.

J Immunother Cancer. 2019 May 7;7(1):123. doi: 10.1186/s40425-019-0584-2.

15.

Association of Anti-Programmed Cell Death 1 Cutaneous Toxic Effects With Outcomes in Patients With Advanced Melanoma.

Quach HT, Dewan AK, Davis EJ, Ancell KK, Fan R, Ye F, Johnson DB.

JAMA Oncol. 2019 Jun 1;5(6):906-908. doi: 10.1001/jamaoncol.2019.0046. No abstract available.

PMID:
30998826
16.

Immune checkpoint inhibitor-associated hypophysitis-World Health Organisation VigiBase report analysis.

Guerrero E, Johnson DB, Bachelot A, Lebrun-Vignes B, Moslehi JJ, Salem JE.

Eur J Cancer. 2019 May;113:10-13. doi: 10.1016/j.ejca.2019.03.002. Epub 2019 Apr 4. No abstract available.

PMID:
30954881
17.

Severe Epididymo-Orchitis and Encephalitis Complicating Anti-PD-1 Therapy.

Quach HT, Robbins CJ, Balko JM, Chiu CY, Miller S, Wilson MR, Nelson GE, Johnson DB.

Oncologist. 2019 Jul;24(7):872-876. doi: 10.1634/theoncologist.2018-0722. Epub 2019 Apr 1.

PMID:
30936376
18.

Adverse Events Associated With Immune Checkpoint Inhibitors-Reply.

Johnson DB, Chandra S, Sosman JA.

JAMA. 2019 Mar 26;321(12):1219-1220. doi: 10.1001/jama.2018.22123. No abstract available.

PMID:
30912830
19.

Mid-term outcomes following primary semi-constrained total knee arthroplasty in patients less than 60 years old, a retrospective review.

Johnson DB Jr, Triplet JJ, Gaines DR, Gupta A, Unverferth KL.

Knee. 2019 Jun;26(3):714-719. doi: 10.1016/j.knee.2019.02.001. Epub 2019 Mar 19.

PMID:
30902516
20.

Clinical Correlates of Response to Anti-PD-1-based Therapy in Patients With Metastatic Melanoma.

Davis EJ, Perez MC, Ayoubi N, Zhao S, Ye F, Wang DY, Sosman JA, Al-Rohil RN, Eroglu Z, Johnson DB.

J Immunother. 2019 Jul/Aug;42(6):221-227. doi: 10.1097/CJI.0000000000000258.

PMID:
30882548
21.

Validation of a Two-Item Food Security Screening Tool in a Dental Setting.

Radandt NE, Corbridge T, Johnson DB, Kim AS, Scott JM, Coldwell SE.

J Dent Child (Chic). 2018 Sep 15;85(3):114-119.

22.

Hematologic Complications of Immune Checkpoint Inhibitors.

Davis EJ, Salem JE, Young A, Green JR, Ferrell PB, Ancell KK, Lebrun-Vignes B, Moslehi JJ, Johnson DB.

Oncologist. 2019 May;24(5):584-588. doi: 10.1634/theoncologist.2018-0574. Epub 2019 Feb 28.

23.

Retrograde Femoral Bone Graft Acquisition Using the Reamer-Irrigator-Aspirator.

Taylor BC, Triplet JJ, Johnson DB, Sharpe BD, Sullivan B, Canini C.

J Long Term Eff Med Implants. 2018;28(3):181-185. doi: 10.1615/JLongTermEffMedImplants.2018027914.

PMID:
30806274
24.

Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors.

Leaf RK, Ferreri C, Rangachari D, Mier J, Witteles W, Ansstas G, Anagnostou T, Zubiri L, Piotrowska Z, Oo TH, Iberri D, Yarchoan M, Salama AKS, Johnson DB, Leavitt AD, Rahma OE, Reynolds KL, Leaf DE.

Am J Hematol. 2019 May;94(5):563-574. doi: 10.1002/ajh.25448. Epub 2019 Mar 13.

PMID:
30790338
25.

Response to Anti-PD-1 in Uveal Melanoma Without High-Volume Liver Metastasis.

Johnson DB, Bao R, Ancell KK, Daniels AB, Wallace D, Sosman JA, Luke JJ.

J Natl Compr Canc Netw. 2019 Feb;17(2):114-117. doi: 10.6004/jnccn.2018.7070.

PMID:
30787124
26.

Loss of BOP1 confers resistance to BRAF kinase inhibitors in melanoma by activating MAP kinase pathway.

Gupta R, Bugide S, Wang B, Green MR, Johnson DB, Wajapeyee N.

Proc Natl Acad Sci U S A. 2019 Feb 19. pii: 201821889. doi: 10.1073/pnas.1821889116. [Epub ahead of print]

PMID:
30782837
27.

Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies.

Pires da Silva I, Glitza IC, Haydu LE, Johnpulle R, Banks PD, Grass GD, Goldinger SMA, Smith JL, Everett AS, Koelblinger P, Roberts-Thomson R, Millward M, Atkinson VG, Guminski A, Kapoor R, Conry RM, Carlino MS, Wang W, Shackleton MJ, Eroglu Z, Lo S, Hong AM, Long GV, Johnson DB, Menzies AM.

Pigment Cell Melanoma Res. 2019 Jul;32(4):553-563. doi: 10.1111/pcmr.12775. Epub 2019 Mar 3.

PMID:
30767428
28.

Targeting tissue factor in advanced solid tumours.

Davis EJ, Johnson DB.

Lancet Oncol. 2019 Mar;20(3):318-319. doi: 10.1016/S1470-2045(18)30912-4. Epub 2019 Feb 8. No abstract available.

PMID:
30745091
29.

Cardiovascular toxicities associated with immune checkpoint inhibitors.

Hu JR, Florido R, Lipson EJ, Naidoo J, Ardehali R, Tocchetti CG, Lyon AR, Padera RF, Johnson DB, Moslehi J.

Cardiovasc Res. 2019 Apr 15;115(5):854-868. doi: 10.1093/cvr/cvz026. Erratum in: Cardiovasc Res. 2019 Apr 15;115(5):868.

PMID:
30715219
30.

A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma.

Ott PA, Pavlick AC, Johnson DB, Hart LL, Infante JR, Luke JJ, Lutzky J, Rothschild NE, Spitler LE, Cowey CL, Alizadeh AR, Salama AK, He Y, Hawthorne TR, Bagley RG, Zhang J, Turner CD, Hamid O.

Cancer. 2019 Apr 1;125(7):1113-1123. doi: 10.1002/cncr.31892. Epub 2019 Jan 28.

PMID:
30690710
31.

Isolated Treatment of a Comminuted Capitate Fracture: A Case Report.

Johnson DB Jr, Triplet JJ, Bernhardt L, Buchan DR, Iorio T.

JBJS Case Connect. 2019 Jan-Mar;9(1):e6. doi: 10.2106/JBJS.CC.18.00166.

PMID:
30676344
32.

Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy.

Shae D, Becker KW, Christov P, Yun DS, Lytton-Jean AKR, Sevimli S, Ascano M, Kelley M, Johnson DB, Balko JM, Wilson JT.

Nat Nanotechnol. 2019 Mar;14(3):269-278. doi: 10.1038/s41565-018-0342-5. Epub 2019 Jan 21.

33.

The Prognostic Significance of Low-Frequency Somatic Mutations in Metastatic Cutaneous Melanoma.

Zhao X, Little P, Hoyle AP, Pegna GJ, Hayward MC, Ivanova A, Parker JS, Marron DL, Soloway MG, Jo H, Salazar AH, Papakonstantinou MP, Bouchard DM, Jefferys SR, Hoadley KA, Ollila DW, Frank JS, Thomas NE, Googe PB, Ezzell AJ, Collichio FA, Lee CB, Earp HS, Sharpless NE, Hugo W, Wilmott JS, Quek C, Waddell N, Johansson PA, Thompson JF, Hayward NK, Mann GJ, Lo RS, Johnson DB, Scolyer RA, Hayes DN, Moschos SJ.

Front Oncol. 2019 Jan 4;8:584. doi: 10.3389/fonc.2018.00584. eCollection 2018.

34.

Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma.

Pires da Silva I, Wang KYX, Wilmott JS, Holst J, Carlino MS, Park JJ, Quek C, Wongchenko M, Yan Y, Mann G, Johnson DB, McQuade JL, Rai R, Kefford RF, Rizos H, Scolyer RA, Yang JYH, Long GV, Menzies AM.

Clin Cancer Res. 2019 Feb 15;25(4):1272-1279. doi: 10.1158/1078-0432.CCR-18-1680. Epub 2019 Jan 10.

PMID:
30630828
35.

Nontraumatic Compartment Syndrome in a Patient with Protein S Deficiency: A Case Report.

Pentz K, Triplet JJ, Johnson DB, Umbel B, Baker TE.

JBJS Case Connect. 2018 Oct-Dec;8(4):e82. doi: 10.2106/JBJS.CC.18.00055.

PMID:
30601765
36.

Biomarkers for Immunotherapy Toxicity: Are Cytokines the Answer?

Johnson DB, Balko JM.

Clin Cancer Res. 2019 Mar 1;25(5):1452-1454. doi: 10.1158/1078-0432.CCR-18-3858. Epub 2018 Dec 26.

PMID:
30587548
37.

Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement.

Johnson DB, Nixon MJ, Wang Y, Wang DY, Castellanos E, Estrada MV, Ericsson-Gonzalez PI, Cote CH, Salgado R, Sanchez V, Dean PT, Opalenik SR, Schreeder DM, Rimm DL, Kim JY, Bordeaux J, Loi S, Horn L, Sanders ME, Ferrell PB Jr, Xu Y, Sosman JA, Davis RS, Balko JM.

JCI Insight. 2018 Dec 20;3(24). pii: 120360. doi: 10.1172/jci.insight.120360.

38.

Acidithiobacillus ferrooxidans.

Quatrini R, Johnson DB.

Trends Microbiol. 2019 Mar;27(3):282-283. doi: 10.1016/j.tim.2018.11.009. Epub 2018 Dec 15.

PMID:
30563727
39.

Clinical characterization of colitis arising from anti-PD-1 based therapy.

Wang DY, Mooradian MJ, Kim D, Shah NJ, Fenton SE, Conry RM, Mehta R, Silk AW, Zhou A, Compton ML, Al-Rohil RN, Lee S, Voorhees AL, Ha L, McKee S, Norrell JT, Mehnert J, Puzanov I, Sosman JA, Chandra S, Gibney GT, Rapisuwon S, Eroglu Z, Sullivan R, Johnson DB.

Oncoimmunology. 2018 Oct 31;8(1):e1524695. doi: 10.1080/2162402X.2018.1524695. eCollection 2019.

PMID:
30546965
40.

Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy.

Saab KR, Mooradian MJ, Wang DY, Chon J, Xia CY, Bialczak A, Abbate KT, Menzies AM, Johnson DB, Sullivan RJ, Shoushtari AN.

Cancer. 2019 Mar 15;125(6):884-891. doi: 10.1002/cncr.31889. Epub 2018 Dec 6.

PMID:
30521084
41.

School Lunch Entrées Before and After Implementation of the Healthy, Hunger-Free Kids Act of 2010.

Mozer L, Johnson DB, Podrabsky M, Rocha A.

J Acad Nutr Diet. 2019 Mar;119(3):490-499. doi: 10.1016/j.jand.2018.09.009. Epub 2018 Nov 23.

PMID:
30473488
42.

Biological Consequences of MHC-II Expression by Tumor Cells in Cancer.

Axelrod ML, Cook RS, Johnson DB, Balko JM.

Clin Cancer Res. 2019 Apr 15;25(8):2392-2402. doi: 10.1158/1078-0432.CCR-18-3200. Epub 2018 Nov 21. Review.

PMID:
30463850
43.

Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study.

Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, Gobert A, Spano JP, Balko JM, Bonaca MP, Roden DM, Johnson DB, Moslehi JJ.

Lancet Oncol. 2018 Dec;19(12):1579-1589. doi: 10.1016/S1470-2045(18)30608-9. Epub 2018 Nov 12.

PMID:
30442497
44.

Computational Immune Monitoring Reveals Abnormal Double-Negative T Cells Present across Human Tumor Types.

Greenplate AR, McClanahan DD, Oberholtzer BK, Doxie DB, Roe CE, Diggins KE, Leelatian N, Rasmussen ML, Kelley MC, Gama V, Siska PJ, Rathmell JC, Ferrell PB, Johnson DB, Irish JM.

Cancer Immunol Res. 2019 Jan;7(1):86-99. doi: 10.1158/2326-6066.CIR-17-0692. Epub 2018 Nov 9.

PMID:
30413431
45.

Immune Checkpoint Inhibitor-Associated Myositis.

Anquetil C, Salem JE, Lebrun-Vignes B, Johnson DB, Mammen AL, Stenzel W, Léonard-Louis S, Benveniste O, Moslehi JJ, Allenbach Y.

Circulation. 2018 Aug 14;138(7):743-745. doi: 10.1161/CIRCULATIONAHA.118.035898. No abstract available.

PMID:
30359135
46.

Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection.

Tio M, Rai R, Ezeoke OM, McQuade JL, Zimmer L, Khoo C, Park JJ, Spain L, Turajlic S, Ardolino L, Yip D, Goldinger SM, Cohen JV, Millward M, Atkinson V, Kane AY, Ascierto PA, Garbe C, Gutzmer R, Johnson DB, Rizvi HA, Joshua AM, Hellmann MD, Long GV, Menzies AM.

Eur J Cancer. 2018 Nov;104:137-144. doi: 10.1016/j.ejca.2018.09.017. Epub 2018 Oct 20.

PMID:
30347289
47.

Increased Reporting of Immune Checkpoint Inhibitor-Associated Diabetes.

Wright JJ, Salem JE, Johnson DB, Lebrun-Vignes B, Stamatouli A, Thomas JW, Herold KC, Moslehi J, Powers AC.

Diabetes Care. 2018 Dec;41(12):e150-e151. doi: 10.2337/dc18-1465. Epub 2018 Oct 10. No abstract available.

PMID:
30305348
48.

Biomechanical Assessment of Torsional Stiffness in a Supracondylar Humerus Fracture Model.

Wallace M, Johnson DB, Pierce W, Iobst C, Riccio A, Wimberly RL.

J Pediatr Orthop. 2019 Mar;39(3):e210-e215. doi: 10.1097/BPO.0000000000001270.

PMID:
30300279
49.

Immune Checkpoint Inhibitor Toxicity in 2018.

Johnson DB, Chandra S, Sosman JA.

JAMA. 2018 Oct 23;320(16):1702-1703. doi: 10.1001/jama.2018.13995. No abstract available.

PMID:
30286224
50.

Identification of trehalose as a compatible solute in different species of acidophilic bacteria.

Galleguillos PA, Grail BM, Hallberg KB, Demergasso CS, Johnson DB.

J Microbiol. 2018 Oct;56(10):727-733. doi: 10.1007/s12275-018-8176-2. Epub 2018 Sep 28.

PMID:
30267316

Supplemental Content

Loading ...
Support Center